Synthis is developing a pipeline of novel targeted immuno-oncology therapies to reverse immune suppression in cancer patients. Instead of directly killing the tumor using a cytotoxic payload, Synthis is employing antibody-drug conjugate technology in a novel way to restore immune-mediated tumor clearance.